Disease progression in myelodysplastic syndromes (MDS) and myelodysplastic-myeloproliferative neoplasms (MDS/MPN) is a major source of mortality. The European Bone Marrow Working Group organized a dedicated workshop to address MDS and MDS/MPN progression, and myeloid neoplasms with histiocytic and lymphoblastic outgrowths in 2019 in Frankfurt, Germany. In this report, we summarize clinical, histopathological, and molecular features of 28 cases. Most cases illustrate that prognostic mutational profiles change during follow-up due to accumulation of high-risk mutations in the trunk clone, and that results from repeated molecular testing can often explain the clinical progression, suggesting that regular genetic testing may predict transformation by early detection of aggressive clones. Importantly, identical mutations can be linked to different clinical behaviors or risks of fibrotic progression and/or transformation in a context-dependent manner, i.e., MDS or MDS/MPN. Moreover, the order of mutational acquisition and the involved cell lineages matter. Several cases exemplify that histiocytic outgrowths in myeloid neoplasms are usually accompanied by a more aggressive clinical course and may be considered harbinger of disease progression. Exceptionally, lymphoblastic transformations can be seen. As best estimable, the histiocytic and lymphoblastic compounds in all occasions were clonally related to the myeloid compound and-where studied-displayed genomic alterations of, e.g., transcription factor genes or genes involved in MAPK signaling that might be mechanistically linked to the respective type of non-myeloid outgrowth.

Bioptická laboratoř Pilsen Czech Republic

Department of Pathology Texas Tech Health Sciences Center El Paso El Paso TX USA

Department of Pathology University Medical Center Utrecht Utrecht Netherlands

Institute of Medical Genetics and Pathology University Hospital of Basel Schoenbeinstrasse 40 CH 4031 Basel Switzerland

Institute of Pathology Helios University Hospital Wuppertal Germany

Institute of Pathology Medical University of Graz Graz Austria

Pathology Unit Department of Pathophysiology and Transplantation University of Milan and Fondazione IRCCS Ca' Granda Maggiore Policlinico Milan Italy

Zobrazit více v PubMed

Hasserjian R P, Orazi A, Brunning R D et al (2017) Myelodysplastic syndromes: overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4

Sperling AS, Gibson CJ, Ebert BL (2017) The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17:5–19 PubMed

Malcovati L, Porta MG, Pascutto C et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603 PubMed

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465 PubMed PMC

Bejar R, Stevenson K, Abdel-Wahab O et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506 PubMed PMC

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP (2017) Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 49:204–212 PubMed

Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellström-Lindberg E, Miyano S, Cazzola M, Ogawa S (2017) Gene expression and risk of leukemic transformation in myelodysplasia. Blood 2017(130):2642–2653

Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E (2014) ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28:2206–2212 PubMed

Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A (2017) Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol 30:1213–1222 PubMed

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, de Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM (2019) Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 104:1935–1949 PubMed PMC

Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A (2016) Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol 91:492–498 PubMed

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML (2015) The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 47:1326–1333 PubMed PMC

Czader M, Orazi A (2015) Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol 144:188–206 PubMed

Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U (2019) Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med 25:103–110 PubMed

Bejar R, Papaemmanuil E, Haferlach et al (2015) Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood 126:907

Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, Maciejewski JP (2019) Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun 10:5386 PubMed PMC

Feurstein S, Thomay K, Hofmann W, Buesche G, Kreipe H, Thol F, Heuser M, Ganser A, Schlegelberger B, Göhring G (2018) Routes of clonal evolution into complex karyotypes in myelodysplastic syndrome patients with 5q deletion. Int J Mol Sci 19:3269 PMC

Cargo C, Bowen D (2017) Individual risk assessment in MDS in the era of genomic medicine. Semin Hematol 54:133–140 PubMed

Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson RK, Graubert TA (2013) Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27:1275–1282 PubMed PMC

Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H (2018) Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. Br J Haematol 182:830–842 PubMed

Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, Kuo MC (2004) Acquisition of FLT3 or N-RAS mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18:466–475 PubMed

Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G (2015) Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39:1367–1374 PubMed PMC

Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, Ohyashiki JH (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359–2360 PubMed

Fu B, Jaso J, Sargent R et al (2014) Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol 27:681–689 PubMed

Zhong B, Medeiros LJ, Wang W (2019) The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis. Br J Haematol 186:396–396 PubMed

Hussein K, Stucki-Koch A, Kreipe H (2018) Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis. Ann Hematol 97:2099–2106 PubMed

de Renzis B, Mansat-De Mas V, Wattel E et al (2013) Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: a matched case control study. Leuk Res Rep 2:64–66 PubMed PMC

Chen C, Lin L, Tang J et al (2006) Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 20:1155–1158 PubMed

Rigolin GM, Cuneo A, Roberti MG (1997) Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 82:25–30 PubMed

Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J, Liu Q, Oluwole F, Hasserjian R, Jones D, Qawi H, Woda B, Raza A (2006) Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 126:789–797 PubMed

Nagata Y, Zhao R, Awada H, Kerr CM, Goyal A, Mirzaev I, Kongkiatkamon S, Nazha A, Radivoyevitch T, Scott J, Sekeres MA, Hobbs BP, Maciejewski JP (2019) How morphologic features are shaped by underlying somatic genotype in MDS. Blood 134:1716

Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY, Tseng MH, Huang CF, Lai YJ, Chiang YC, Lee FY, Liu MC, Liu CW, Liu CY, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2014) Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 4:e177 PubMed PMC

Campidelli C, Agostinelli C, Stitson R, Pileri SA (2009) Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol 132:426–437 PubMed

Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y (2018) Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology 23:17–24 PubMed

Pileri S, Ascani S, Cox M et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21:340–350 PubMed

Li Z, Stölzel F, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca G (2015) Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia 29:2113–2116 PubMed PMC

Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, de Botton S (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia 32:2008–2081 PubMed

Li H, Hasserjian RP, Kroft SH, Harrington AM, Wheaton SE, Pildain A, Ewalt MD, Gratzinger D, Hosking P, Olteanu H (2016) Pure erythroid leukemia and erythroblastic sarcoma evolving from chronic myeloid neoplasms. Am J Clin Pathol 145:538–551 PubMed PMC

Visconte V, O Nakashima M, J Rogers H (2019) Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features. Cancers (Basel) 11:1844

Lin CC, Hou HA, Chou WC, Kuo YY, Wu SJ, Liu CY, Chen CY, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Hsu SC, Ko BS, Tsay W, Chen YC, Tien HF (2014) SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution. Am J Hematol 89:E109–E115 PubMed

Singh ZN, Post GR, Kiwan E, Maddox AM (2011) Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. Clin Lymphoma Myeloma Leuk 11:293–297 PubMed

Song J, Moscinski L, Zhang H, Zhang X, Hussaini M (2019) Does SF3B1/TET2 double mutation portend better or worse prognosis than isolated SF3B1 or TET2 mutation? Cancer Genomics Proteomics 16:91–98 PubMed PMC

Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, Pardanani A, Tefferi A (2012) SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 26:1135–1137 PubMed

Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP (2013) Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 26:751–761 PubMed

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable. Blood 132:2100–2103 PubMed PMC

Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T (2018) The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. Haematologica 103:e192–e195 PubMed PMC

Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 90:653–656 PubMed

Ammatuna E, Eefting M, van Lom et al (2015) Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol 94:879-880

Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE (2016) Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7:14251–14258 PubMed PMC

Jung SI, Cho HS, Lee CH, Kim KD, Ha JO, Kim MK, Lee KH, Hyun MS (2008) Two cases of trisomy 19 as a sole chromosomal abnormality in myeloid disorders. Korean J Lab Med 28:174–178 PubMed

Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651 PubMed PMC

Vitte F, Fabiani B, Bénet C, Dalac S, Balme B, Delattre C, Vergier B, Beylot-Barry M, Vignon-Pennamen D, Ortonne N, Algros MP, Carlotti A, Samaleire D, Frouin E, Levy A, Laroche L, Theate I, Monnien F, Mugneret F, Petrella T (2012) Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations. A study of 42 cases. Am J Surg Pathol 36:1302–1316 PubMed

Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L (2012) Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res 36:72–80 PubMed

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop M’K, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E (2019) Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33:2466–2480 PubMed

Zhang H, Wilmot B, Bottomly D, Dao KHT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW (2019) Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134:867–879 PubMed PMC

Patnaik MM, Vallapureddy R, Lasho TL et al (2018) A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia 32:1850–1856 PubMed

DeAngelo DJ, George TI, Linder A et al (2018) Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 32:470–478 PubMed

Tanna S, Ustun C (2009) Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit? Int J Hematol 90:597–600 PubMed

Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, Hebeda KM (2018) Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 97:2117–2128 PubMed PMC

Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT (2017) Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol 44:1075–1079 PubMed

Boiocchi L, Espinal-Witter R, Geyer JT, Steinhilber J, Bonzheim I, Knowles DM, Fend F, Orazi A (2013) Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol 26:204–212 PubMed

Mori M, Matsushita A, Takiuchi Y, Arima H, Nagano S, Shimoji S, Kimura T, Inoue D, Tabata S, Yanagita S, Nagai K, Imai Y, Takahashi T (2010) Histiocytic sarcoma and underlying chronic myelomonocytic leukemia: a proposal for the developmental classification of histiocytic sarcoma. Int J Hematol 92:168–173 PubMed

Arber DA, Brunning RD, Le Beau M et al (2017) Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4th edn. IARC Press, Lyon, pp 130-149

Shanmugam V, Morgan EA, DeAngelo DJ, Kim AS (2019) Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. J Clin Pathol 72:93–96 PubMed

Ansari J, Naqash AR, Munker R, el-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P, Shackelford RE (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97:9–16 PubMed

Russell L, Shaw NJ, Eden OB (1989) Hemophagocytosis and acute monoblastic leukemia. Pediatr Hematol Oncol 6:367–371 PubMed

Unal S, Cetin M, Kutlay NY, Elmas SA, Gumruk F, Tukun A, Tuncer M, Gurgey A (2010) Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia. Ann Hematol 89:359–364 PubMed

Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, la Rosée P, Kantarjian HM (2017) A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123:3229–3240 PubMed PMC

Wang LX, Fei XM, Lu YL, Shi XF, Jiang Q, You HY, Ba R, Zhu Y (2010) Acute myeloid leukemia initially presenting as hemophagocytic lymphohistiocytosis - a case report and review of the literature. Leuk Res 34:e46–e49 PubMed

Bodmer A, Menter T, Juskevicius D, Arranto C, Wenzel F, Dirnhofer S, Tzankov A (2017) Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin. Virchows Arch 470:469–473 PubMed

Orazi A, Chiu R, O'Malley DP, Czader M, Allen SL, An C, Vance GH (2006) Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 19:1536–1545 PubMed

Tzankov A, Hebeda K, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U (2017) Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 96:765–777 PubMed

Vardiman JW, Melo JV, Baccarani M et al (2017) Chronic myeloid leukemia, BCR-ABL1-positive. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4th edn. IARC Press, Lyon, pp 30-36

Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL (2008) BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 112:5190–5192 PubMed PMC

Winter SS, Greene JM, McConnell TS, Willman CL (1999) Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone. Leukemia 13:2007–2011 PubMed

Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Müller MC, Hochhaus A, Haferlach T, Haferlach C (2011) A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25:557–560 PubMed

Klumb CE, Barbosa TDC, Nestal de Moraes G et al (2019) IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia. Pediatr Blood Cancer 66:e27570 PubMed

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110–114 PubMed

Menter T, Lundberg P, Wenzel F, Dirks J, Fernandez P, Friess D, Dirnhofer S, Tzankov A (2019) RUNX1 mutations can lead to aberrant expression of CD79a and PAX5 in acute myelogenous leukemias: a potential diagnostic pitfall. Pathobiology 86:162–166 PubMed

Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B (2004) PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 64:7399–7404 PubMed

Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J (2017) Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias (de novo and blast phase CML). Am J Hematol 92:E3–E4 PubMed

Kim AS, Goldstein SC, Luger S, Van Deerlin VM, Bagg A (2008) Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? Am J Clin Pathol 129:639–648 PubMed

De Bie J, Demeyer S, Gielen O et al (2018) BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL. Hemasphere 2:e42 PubMed PMC

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M (2017) Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130:2027–2031 PubMed PMC

Zhang M, Lu J, Wang X, Cen J, Fan G, Hu S (2013) Early precursor T-lymphoblastic leukaemia/lymphoma arising from paediatric chronic myeloid leukaemia – unusual lymph node blast crisis. Br J Haematol 161:136–139 PubMed

Guo ZP, Tan YH, Li JL, Xu ZF, Chen XH, Xu LR (2018) Acute pro-B-cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: a case report with literature review. Oncol Lett 15:9745–9750 PubMed PMC

Kouides PA, Bennett JM (1995) Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome. Am J Hematol 49:157–162 PubMed

Park TS, Song J, Lee KA, Lee SG, Yoon S, Kim JS, Lyu CJ, Choi JR (2007) der(1;15)(q10;q10) is a rare nonrandom whole-arm translocation in patients with acute lymphoblastic leukemia. Cancer Genet Cytogenet 179:132–135 PubMed

Terada T (2012) TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma. Int J Clin Exp Pathol 5:167–170 PubMed

Hu T, Murdaugh R, Nakada D (2017) Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia. Front Oncol 7:268 PubMed PMC